Comparing the current results to its competitors, Invivyd Inc reported Revenue increase in the 2 quarter 2026 by 21.2 % year on year. The sales growth was above Invivyd Inc 's competitors' average revenue growth of 2.35 %, achieved in the same quarter.
Invivyd Inc 's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industry is highly competitive and marked by rapid technological advancements and a strong focus on intellectual property. Competition includes major pharmaceutical companies, specialty pharmaceutical firms, established and emerging biotechnology companies, academic research institutions, governmental agencies, and both public and private research organizations worldwide. Many competitors possess greater financial resources and expertise in research and development, clinical trials, manufacturing, regulatory approvals, and commercialization. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger companies. The company cites its approach, strategy, scientific and manufacturing capabilities, know-how, partnerships, and experience as factors contributing to its competitive position.
July 1, 2024
Invivyd Joins Prestigious Russell 2000 and Russell 3000 Indexes, Solidifying Its Position in the Biopharmaceutical IndustryWALTHAM, Mass., July 1, 2024 - Invivyd, Inc. (Nasdaq: IVVD), a leading biopharmaceutical company dedicated to combatting serious viral infectious diseases, is excited to announce its inclusion in the prestigious Russell 2000 Index and the broad-market Russell 3000 Index. This strategic move, effective today with the opening of U.S. equity markets, is a significant milestone for Invivyd and reinforces its growing influence in the biopharmaceutical industry.The Russell indexes, widely regarded as critical indicators of stock market performance, are compiled by FTSE Russell, a subsidiary of...
April 15, 2024
Invivyd Receives HCPCS Reimbursement Codes and FDA Authorization for PEMGARDA: A Breakthrough Prophylaxis Against COVID-19WALTHAM, Mass., March 22, 2024 - Invivyd, Inc. (Nasdaq: IVVD), a renowned biopharmaceutical company committed to safeguarding the vulnerable population against severe viral infectious diseases, announced today a significant milestone for PEMGARDA (pemivibart). Previously known as VYD222, this half-life extended monoclonal antibody (mAb) has been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older) who suffer from moderate-to-severe immune comp...
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.
Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.
Sources:
Invivyd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Invivyd Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
